Apr 152016
Talent4Boards - Great Talent builds Great Boards
– USA, MA – Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced the appointment of Lynn Seely, M.D.
Blueprint Medicines appoints Dr Lynn Seely to the Board of Directors
From:: Blueprint Medicines appoints Dr Lynn Seely to the Board of Directors
Sorry, the comment form is closed at this time.